NeuroScientific Biopharmaceuticals Limited Sustainability Profile
NeuroScientific Biopharmaceuticals Limited, often referred to as NeuroScientific, is a pioneering biopharmaceutical company headquartered in Australia. Founded in 2015, the company focuses on developing innovative treatments for neurological disorders, positioning itself at the forefront of the biopharmaceutical industry. With a strong emphasis on research and development, NeuroScientific is dedicated to advancing its core products, including its proprietary drug candidates aimed at addressing conditions such as chronic pain and neurodegenerative diseases. The company’s unique approach combines cutting-edge science with a commitment to improving patient outcomes, setting it apart in a competitive market. NeuroScientific has achieved significant milestones, including successful clinical trials and partnerships that enhance its market presence. As it continues to expand its operational reach, NeuroScientific remains committed to delivering transformative therapies that address unmet medical needs.
DitchCarbon Score
How does NeuroScientific Biopharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
NeuroScientific Biopharmaceuticals Limited's score of 14 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
NeuroScientific Biopharmaceuticals Limited's reported carbon emissions
NeuroScientific Biopharmaceuticals Limited, headquartered in Australia, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that NeuroScientific Biopharmaceuticals may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. As the biopharmaceutical industry increasingly prioritises environmental responsibility, it will be essential for the company to consider developing and implementing strategies to measure and reduce its carbon emissions in the future.
How Carbon Intensive is NeuroScientific Biopharmaceuticals Limited's Industry?
How Carbon Intensive is NeuroScientific Biopharmaceuticals Limited's Location?
NeuroScientific Biopharmaceuticals Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
NeuroScientific Biopharmaceuticals Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
